RET and medullary thyroid gland carcinoma: Almost all patients (98%) with MEN 2A, MEN 2B, and FMTC show RET germline mutations, whereas somatic RET mutations are seen in approximately 45–70% of sporadic MTC [19,22,23,24,25].